AEMD Stock Price Drops 24% Following Disappointing Earnings Report
ByAinvest
Friday, Jun 27, 2025 6:51 pm ET1min read
AEMD--
The earnings report fell short of market expectations, with analysts projecting an earnings per share of -$1.09. The stock's price target range provided by Wall Street analysts was between USD 4.50 and USD 56.00, with an average target price of USD 30.25, suggesting an upside of 1,628.57% from the current price of USD 1.75 [2].
GuruFocus estimates an impressive 5,036.08% upside for AEMD based on its GF Value metric, which is calculated using historical trading multiples, past business growth, and future performance forecasts. The estimated GF Value for AEMD is USD 99.64 over the next year [3].
Investors are concerned about the company's future prospects, and the market's reaction to the earnings report will be closely monitored. Despite the disappointing results, the consensus recommendation from brokerage firms is currently "Outperform," indicating a favorable outlook among analysts [2].
References:
[1] https://www.marketscreener.com/quote/stock/AETHLON-MEDICAL-INC-22881435/news/Aethlon-Medical-Inc-Reports-Earnings-Results-for-the-Full-Year-Ended-March-31-2025-50356636/
[2] https://www.gurufocus.com/news/2948836/aethlon-medical-aemd-poised-to-report-earnings-with-consensus-expectations-aemd-stock-news
[3] https://www.gurufocus.com/news/2949288/aethlon-medical-aemd-reports-widerthanexpected-annual-loss
AEMD stock plummeted 24% after the company reported earnings that failed to meet market expectations. Investors are disappointed with the financial results, leading to uncertainty about the company's future prospects. Wall Street analysts forecast an average target price of $4.50, implying an upside of 131.96% from the current price. The estimated GF Value for Aethlon Medical Inc is $99.64, suggesting a 5036.08% upside.
Aethlon Medical Inc (AEMD) stock experienced a significant drop of 24% following the release of its earnings report for the full year ended March 31, 2025. The company reported a net loss of USD 13.39 million, up from USD 12.21 million a year ago. The basic loss per share from continuing operations was USD 8.58, compared to USD 38.87 a year ago [1].The earnings report fell short of market expectations, with analysts projecting an earnings per share of -$1.09. The stock's price target range provided by Wall Street analysts was between USD 4.50 and USD 56.00, with an average target price of USD 30.25, suggesting an upside of 1,628.57% from the current price of USD 1.75 [2].
GuruFocus estimates an impressive 5,036.08% upside for AEMD based on its GF Value metric, which is calculated using historical trading multiples, past business growth, and future performance forecasts. The estimated GF Value for AEMD is USD 99.64 over the next year [3].
Investors are concerned about the company's future prospects, and the market's reaction to the earnings report will be closely monitored. Despite the disappointing results, the consensus recommendation from brokerage firms is currently "Outperform," indicating a favorable outlook among analysts [2].
References:
[1] https://www.marketscreener.com/quote/stock/AETHLON-MEDICAL-INC-22881435/news/Aethlon-Medical-Inc-Reports-Earnings-Results-for-the-Full-Year-Ended-March-31-2025-50356636/
[2] https://www.gurufocus.com/news/2948836/aethlon-medical-aemd-poised-to-report-earnings-with-consensus-expectations-aemd-stock-news
[3] https://www.gurufocus.com/news/2949288/aethlon-medical-aemd-reports-widerthanexpected-annual-loss
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet